STOCK TITAN

Eton Pharmaceuticals (ETON) CEO exercises options and RSUs, increasing stake

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. President & CEO Sean Brynjelsen reported only equity acquisitions. He exercised employee stock options covering 200000.0000 shares of common stock at an exercise price of 1.3700 on July 14, 2026, and converted 27500.0000 shares from restricted stock units on July 12, 2026. After these derivative exercises, he directly holds 1061194.0000 common shares, with no sales, gifts, or tax-withholding dispositions reported.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider BRYNJELSEN SEAN
Role President & CEO
Type Security Shares Price Value
Exercise Employee Stock Option 200,000 $0.00 --
Exercise Common Stock 200,000 $1.37 $274K
Exercise Restricted Stock Units 27,500 $0.00 --
Exercise Common Stock 27,500 -- --
Holdings After Transaction: Employee Stock Option — 0 shares (Direct); Common Stock — 1,061,194 shares (Direct); Restricted Stock Units — 0 shares (Direct)
Footnotes (1)
  1. On July 12, 2022, the reporting person was granted 110,000 restricted stock units which vested in four equal installments beginning July 12, 2023. The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments.
Option shares exercised 200000.0000 shares Employee Stock Option into common stock on 2026-07-14
RSUs converted 27500.0000 shares Restricted Stock Units into common stock on 2026-07-12
Exercise price 1.3700 Conversion or exercise price for 200000.0000 option shares
Shares held after transactions 1061194.0000 shares Direct common stock ownership following July 14, 2026 exercise
Total derivative shares exercised 227500.0000 shares ExerciseShares in transaction summary for Form 4
RSU grant size 110000 units Restricted stock units granted July 12, 2022, vesting in four equal installments
Option expiration date 2027-11-09 Expiration date of Employee Stock Option exercised on 2026-07-14
Employee Stock Option financial
"security_title is listed as "Employee Stock Option" for 200000.0000 shares"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Restricted Stock Units financial
"security_title is shown as "Restricted Stock Units" for 27500.0000 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"transaction_code_description notes an "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
total_shares_following_transaction financial
"field "total_shares_following_transaction" shows 1061194.0000 common shares"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did ETON’s CEO Sean Brynjelsen report in this Form 4?

Sean Brynjelsen reported only equity acquisitions. He exercised options into 200000.0000 common shares on July 14, 2026 and converted 27500.0000 restricted stock units into common shares on July 12, 2026, with no disposals or sales disclosed.

How many ETON shares does CEO Sean Brynjelsen hold after these transactions?

Following the reported derivative exercises, Sean Brynjelsen directly holds 1061194.0000 shares of Eton Pharmaceuticals common stock. This reflects the addition of 227500.0000 shares from option and restricted stock unit conversions reported in this Form 4 filing.

Were any ETON shares sold or disposed of in Sean Brynjelsen’s latest Form 4?

No. The Form 4 reports no sales, gifts, or tax-withholding dispositions. All transactions are coded “M” for derivative exercises or conversions, indicating movements from options and restricted stock units into common stock, not open-market buying or selling.

What option exercise did ETON’s CEO complete on July 14, 2026?

On July 14, 2026, Sean Brynjelsen exercised an Employee Stock Option for 200000.0000 underlying common shares at an exercise price of 1.3700. The option was originally granted on November 10, 2017 and was scheduled to expire on November 9, 2027.

What restricted stock unit activity involving ETON shares occurred on July 12, 2026?

On July 12, 2026, 27500.0000 Restricted Stock Units were converted into common stock for Sean Brynjelsen. These RSUs are part of a 110000-unit award granted on July 12, 2022, which vests in four equal annual installments beginning July 12, 2023.

How many derivative shares did ETON’s CEO exercise in total in this Form 4?

In total, the filing shows exercises or conversions for 227500.0000 derivative shares. This includes 200000.0000 shares from an Employee Stock Option and 27500.0000 shares from Restricted Stock Units, all converted into common stock without any reported disposals.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BRYNJELSEN SEAN

(Last)(First)(Middle)
C/O ETON PHARMACEUTICALS, INC.
21925 W. FIELD PARKWAY, SUITE 235

(Street)
DEERPARK ILLINOIS 60010-7208

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/12/2026M27,500A(1)861,194D
Common Stock07/14/2026M200,000A$1.371,061,194D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$007/12/2026M27,500 (1) (1)Common Stock27,500$00D
Employee Stock Option$1.3707/14/2026M200,00011/10/2017(2)11/09/2027Common Stock200,000$00D
Explanation of Responses:
1. On July 12, 2022, the reporting person was granted 110,000 restricted stock units which vested in four equal installments beginning July 12, 2023.
2. The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments.
Remarks:
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for an indefinite duration.
/s/ Judith Matthews07/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)